{
  "payload": {
    "molecule": "Pirfenidone",
    "recommendation": "Investigate",
    "market_score": 72,
    "innovation_story": "Pirfenidone maintains a consistent anti-fibrotic signal across PF-ILD cohorts with manageable liver monitoring, opening a viable path for label expansion once follow-up registrational data matures.",
    "workers": {
      "clinical": {
        "summary": "Phase 2b study NCT01907900 slowed FVC decline by ~45 mL vs placebo over 24 weeks; benefit also seen in registry patients failing nintedanib.",
        "confidence": 0.78,
        "confidence_band": "high",
        "evidence": [
          {
            "type": "Trial",
            "text": "Pirfenidone slowed the decline in forced vital capacity versus placebo across progressive fibrosing interstitial lung disease patients.",
            "url": "https://clinicaltrials.gov/study/NCT01907900",
            "confidence": 0.84
          },
          {
            "type": "Registry",
            "text": "Real-world compassionate use program reported stabilised FVC over 6 months in refractory IPF cases.",
            "url": "https://example.org/registry",
            "confidence": 0.6
          }
        ]
      },
      "literature": {
        "summary": "Multiple PMC articles describe TGF-beta modulation and anti-inflammatory properties supporting use beyond IPF.",
        "confidence": 0.74,
        "confidence_band": "medium",
        "evidence": [
          {
            "type": "Mechanism",
            "text": "Pirfenidone downregulates profibrotic cytokines and reduces collagen deposition in murine bleomycin models.",
            "url": "https://pubmed.ncbi.nlm.nih.gov/33411160/",
            "confidence": 0.72
          }
        ]
      },
      "patent": {
        "summary": "Key Genentech filings on pirfenidone combinations expire 2028-2030; no blocking claims on PF-ILD indication found.",
        "confidence": 0.63,
        "confidence_band": "medium",
        "evidence": [
          {
            "type": "Patent",
            "text": "US20190234567 lists pirfenidone + nintedanib combos but indication claims are limited to IPF.",
            "url": "https://patents.google.com/patent/US20190234567",
            "confidence": 0.58
          }
        ]
      },
      "market": {
        "summary": "~120k PF-ILD patients across US/EU with limited options; opportunity >$1.4B with modest uptake from pulmonologists.",
        "confidence": 0.69,
        "confidence_band": "medium",
        "evidence": [
          {
            "type": "Market",
            "text": "IQVIA analogue sizing suggests $1.4B PF-ILD TAM by 2030 with 6% CAGR.",
            "url": "https://example.org/market",
            "confidence": 0.65
          }
        ]
      }
    },
    "quality": {
      "status": "needs_attention",
      "alerts": {
        "literature": [
          "Low evidence coverage (1/2)",
          "Evidence monoculture (single unique source)"
        ]
      }
    }
  }
}
